This study was designed to evaluate whether interleukin-23 receptor (IL-23R) polymorphisms were associated with Crohn's disease (CD) susceptibility.PubMed, MEDLINE, and Embase were searched for studies that investigated the IL-23R variants and CD risk. Meta-analysis from all eligible case-control studies was performed to assess the purported associations.Our analysis found that variant minor alleles for single nucleotide polymorphisms (SNPs) rs11209026 (Arg381Gln) (P < 0.00001, OR = 0.43, 95% CI (0.37-0.50)) and rs7517847 (G/G vs. T/T, P < 0.00001, OR = 0.49, 95% CI (0.38-0.64); G/G vs. T/G + T/T, (P < 0.00001, OR = 0.56, 95% CI (0.44-0.72); T/G + G/G vs. T/T, (P < 0.00001, OR = 0.71, 95% CI (0.64-0.79) of IL-23R were inversely associated with CD risk; sensitivity analysis also indicated that Caucasian population with a variant of Arg381Gln has a decreased risk for developing CD (P < 0.00001, OR = 0.43, 95% CI (0.36-0.50)).Our meta-analysis supports that two polymorphisms (Arg381Gln and rs7517847) within the IL-23R gene may be considered to be protective factors against developing CD. Further large case-control studies especially concerning ethnicity differences and genotype-phenotype interaction should be performed to clarify possible roles of IL-23R in CD.